Back to results
US 10,702,488 B2Granted
PPAR-γ activators, HDAC inhibitors and their therapeutical usages
AssigneeTheriac Biomedical Inc.
InventorTony Antakly
Life of this patent
Estimating the term…
Abstract
The invention relates to a composition for induction of activity of a nuclear receptor PPARγ and inhibition of HDAC in a subject in need thereof, which comprises a synergistic combination of benzoate and phenylbutyrate and/or phenylacetate in association with a pharmaceutical carrier.
Claims7
A pharmaceutical composition for induction of activity to improve disease symptoms by regulating a gene expression using histone deacetylase inhibitors (HDAC) activity in multiple target cells comprising:
- a) a nuclear peroxisome proliferator-activated receptors PPAR, particularly PPARγ that improves symptoms of at least one of inflammation, pain, autoimmune diseases, neurodegenerative inflammatory diseases, cancer and diabetes type 2 to replace PPARγ agonists in the multiple target cells,
- b) the histone deacetylase inhibitors HDAC which possess anti-proliferative and anti-pain activity in a subject in need thereof,
- c) a synergistic combination of benzoate and phenylbutyrate and/or phenylacetate in association with a pharmaceutical carrier;
- wherein the benzoate is present at a dosage of 10 to 250 mg/kg and phenylbutyrate and/or phenylacetate is present at a dosage of 0.1 to 1000 mg/kg.
1 more element
Dependencies are inferred from the claim text.